Literature DB >> 24001961

Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?

John R Giudicessi1, Michael J Ackerman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24001961      PMCID： PMC3906667          DOI： 10.3949/ccjm.80a.13077

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


× No keyword cloud information.
  15 in total

1.  [Torsade de pointes and cardiorespiratory arrest induced by azithromycin in a patient with congenital long QT syndrome].

Authors:  E Arellano-Rodrigo; A García; L Mont; M Roqué
Journal:  Med Clin (Barc)       Date:  2001-06-23       Impact factor: 1.725

Review 2.  Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.

Authors:  Douglas Shaffer; Sarah Singer; Joyce Korvick; Peter Honig
Journal:  Clin Infect Dis       Date:  2002-06-19       Impact factor: 9.079

3.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

Review 4.  Data mining for signals in spontaneous reporting databases: proceed with caution.

Authors:  Wendy P Stephenson; Manfred Hauben
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

Review 5.  Quantitative signal detection using spontaneous ADR reporting.

Authors:  A Bate; S J W Evans
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-06       Impact factor: 2.890

6.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

Review 7.  Antimicrobial-associated QT interval prolongation: pointes of interest.

Authors:  Robert C Owens; Thomas D Nolin
Journal:  Clin Infect Dis       Date:  2006-11-08       Impact factor: 9.079

8.  Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.

Authors:  Peter Milberg; Lars Eckardt; Hans-Jürgen Bruns; Julia Biertz; Shahram Ramtin; Nico Reinsch; Dirk Fleischer; Paulus Kirchhof; Larissa Fabritz; Günter Breithardt; Wilhelm Haverkamp
Journal:  J Pharmacol Exp Ther       Date:  2002-10       Impact factor: 4.030

9.  Clinical toleration and safety of azithromycin.

Authors:  S Hopkins
Journal:  Am J Med       Date:  1991-09-12       Impact factor: 4.965

10.  Use of azithromycin and death from cardiovascular causes.

Authors:  Henrik Svanström; Björn Pasternak; Anders Hviid
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245
View more
  19 in total

1.  Evaluation of azithromycin induced cardiotoxicity in rats.

Authors:  Ozlem Atli; Sinem Ilgin; Hakan Altuntas; Dilek Burukoglu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

Review 3.  Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.

Authors:  J R Giudicessi; M J Ackerman; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-14       Impact factor: 3.598

4.  Cardiovascular events and safety outcomes associated with azithromycin therapy: a meta-analysis of randomized controlled trials.

Authors:  Ziyad S Almalki; Jeff Jianfei Guo
Journal:  Am Health Drug Benefits       Date:  2014-09

Review 5.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

Review 6.  Role of Ureaplasma Respiratory Tract Colonization in Bronchopulmonary Dysplasia Pathogenesis: Current Concepts and Update.

Authors:  Rose Marie Viscardi; Suhas G Kallapur
Journal:  Clin Perinatol       Date:  2015-10-09       Impact factor: 3.430

7.  Incidence of Sustained Ventricular Tachycardia in Patients with Prolonged QTc After the Administration of Azithromycin: A Retrospective Study.

Authors:  Steven P Sears; Trevor W Getz; Christopher O Austin; William C Palmer; Evelyn A Boyd; Fernando F Stancampiano
Journal:  Drugs Real World Outcomes       Date:  2016-03

8.  Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.

Authors:  Jules C Hancox; Mehrul Hasnain; W Victor R Vieweg; Michael Gysel; Michelle Methot; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2014-04

9.  Does macrolide use confer risk of out-of-hospital cardiac arrest compared with penicillin V? A Danish national case-crossover and case-time-control study.

Authors:  Frederik Boetius Hertz; Aksel Jensen; Jenny D Knudsen; Magnus Arpi; Charlotte Andersson; Gunnar H Gislason; Lars Køber; Christian Torp-Pedersen; Freddy Lippert; Peter E Weeke
Journal:  BMJ Open       Date:  2018-02-23       Impact factor: 2.692

Review 10.  An eye for azithromycin: review of the literature.

Authors:  Kostas A Kagkelaris; Olga E Makri; Constantine D Georgakopoulos; George D Panayiotakopoulos
Journal:  Ther Adv Ophthalmol       Date:  2018-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.